Updated glucose management indicator (GMI) better aligns with HbA1c than current GMI: implications for clinical practice and reporting.

Richard M Bergenstal¹, Yongjin Xu², Timothy C Dunn², Pratik Choudhary³, Ramzi A Ajjan⁴

¹International Diabetes Center, HealthPartners Institute, Minneapolis, MN, USA. richard.bergenstal@parknicollet.com.

²Clinical Affairs, Abbott Diabetes Care, Alameda, CA, USA.

³Diabetes Research Centre, University of Leicester, Leicester, UK.

⁴The LIGHT Laboratories, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

PubMed PMC DOI PDF

Abstract

AIMS/HYPOTHESIS: The continuous glucose monitoring (CGM)-derived glucose management indicator (GMI) is valuable to people with diabetes, and healthcare professionals and organisations for assessing overall glucose levels, optimising management plans. However, the current GMI can both over- and underestimate HbA1c, which can create clinical difficulties. Our aim was to improve the agreement between…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.